Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Parabilis Medicines reported third-quarter 2026 financial results, ending the period with $1.1 billion in cash and marketable securities. The company reached alignment with the FDA on the Phase 3 registrational trial design for zolucatetide in desmoid tumors, with initiation planned for the first half of 2027. Additionally, the company entered a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination therapies for metastatic colorectal cancer.
Term
Q3 2026
“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
“The progress across our portfolio continues to strengthen our conviction in the ability of our Helicon platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients’ lives.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
Yarrow Bioscience reported third quarter 2026 financial results, ending the period with $268.9 million in cash following a $172.5 million public offering. The company is currently enrolling patients in its Phase 2a/2b DIRECTION-GD trial for YB-101, with topline data expected in the second half of 2027.
“We made significant progress in the third quarter, including dosing our first patient in the Phase 2a portion of the DIRECTION-GD trial and strengthening our balance sheet through the completion of our merger and subsequent public offering. The financing extends our expected cash runway into 2030 and positions us to advance YB-101 in Graves’ disease and prepare for our next steps in thyroid eye disease.”
Rebecca V. Frey, PharmD, President and Chief Executive Officer
Octave Intelligence reported Q3 2026 financial results with total revenue of $415 million and net income of $59 million. The company also announced that its Board of Directors approved a new $200 million share repurchase program, reflecting confidence in its recurring revenue strategy and free cash flow growth.
“Our third quarter results were in line with our expectations, and we remain on track to achieve our outlook for the full year. ARR grew 7% over the prior year to $1.17 billion, and SaaS revenue grew 18%, as we continue our focused shift toward recurring revenue. Product innovation and go-to-market improvements continued to gain traction this quarter, and we’re carrying that momentum into the fourth quarter”
Mattias Stenberg, Chief Executive Officer
“Additionally, our Board of Directors recently approved a $200 million share repurchase program, a decision that reflects its confidence in our company strategy, medium-term financial targets, and ability to grow free cash flow.”
Century Therapeutics reported a total asset increase to $262.6 million as of September 30, 2026, driven by a significant increase in common stock issuance and long-term investments. The company's accumulated deficit grew to $871.6 million, reflecting ongoing development costs for its iPSC-derived immune cell therapies.
Ftai Infrastructure CEO and President Kenneth J. Nicholson Buys $1.53M of Stock
Kenneth J. Nicholson, CEO and President, bought 400,000 shares of Ftai Infrastructure Inc. at $3.83 a share, worth $1.53M in total on Nov 10, 2026. Shares held after the trade: 2,575,539 (+18.4%).
Generate Biomedicines, Inc. is a clinical-stage biotechnology company utilizing its AI-driven 'Generate Platform' for drug discovery. As of October 29, 2026, the company had 129,096,666 shares of common stock outstanding and is classified as an emerging growth company and a non-accelerated filer.
Standard Nuclear, Inc. reported a significant revenue increase to $11.3 million for the first nine months of 2026, driven by new product revenue, though it maintained a net loss of $24.2 million. The company successfully completed an IPO and a 2-for-1 stock split, ending the period with a substantially strengthened cash position of $223.1 million.
Cyngn Inc. reported its Q3 2026 financial results, highlighting year-to-date revenue of $405.5 thousand and a cash position of $34.9 million with no debt. The company noted commercial progress including a follow-on order from a Fortune 100 heavy equipment manufacturer and the launch of its DriveMod EasyLaunch program to lower adoption barriers for autonomous industrial vehicles.
EyePoint reported Q3 2026 financial results and announced a strategic prioritization of its DURAVYU Phase 3 program in Diabetic Macular Edema (DME). The company expects this prioritization to generate $30 million in annualized savings following mixed Phase 3 results in wet AMD.
“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.”
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
Jose A. Fernandez stepped down as Co-Chief Operating Officer of StepStone Group Inc. effective November 11, 2026, though he will remain with the firm as a Partner. Consequently, Jason P. Ment ceased to serve as Co-COO but will continue as President, with corporate operational functions now overseen by CEO Scott W. Hart and Mr. Ment.
Mobility Global Inc. completed its separation from S&P Global on July 1, 2026, becoming an independent publicly traded company. For the nine months ended September 30, 2026, the company reported revenue of $1,401 million and net income of $150 million, compared to $1,304 million and $194 million in the prior year period, respectively.
Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.
Mobility Global reported its first full quarter as a standalone public company, with revenue increasing 7.4% year-over-year to $478 million. The company reported net income of $42 million and adjusted EBITDA of $195 million, while also authorizing a new $800 million share repurchase program.
Term
Q3 2026
“Our first full quarter as a standalone public company was a solid one, with growth stepping up from the first half across both segments. We are bringing our CARFAX and B2B businesses together as One Mobility Global and applying AI to our proprietary data, trusted brands and deeply embedded customer relationships to deliver more value to our customers and drive growth.”
Bill Eager, Chief Executive Officer of Mobility Global
For the quarter ended September 30, 2026, NIQ Global Intelligence reported revenues of $1,119.1 million and net income attributable to NIQ of $35.8 million, a significant improvement from the $198.6 million loss in the prior year period. The company's balance sheet shows $572.6 million in cash and total debt of approximately $3.55 billion as of the end of the third quarter.
BK Technologies reported record third-quarter revenue of $25.3 million, driven by strong federal demand and the adoption of its BKR 5000 Orange radio by the U.S. Forest Service. The company achieved a gross margin of 50.7% and grew its cash position to $29.2 million with no debt. Additionally, the company doubled its share repurchase authorization to $10 million and made a $3.0 million strategic investment in software provider Tango Tango.
Term
Q3 2026
“Our third quarter results underscore the durability of our business model and demonstrate our ability to consistently deliver profitable growth. Federal demand was a key growth driver leading to record third quarter revenue of $25.3 million, a gross margin above 50% and an increase in net income of 9% that outpaced revenue growth.”
Kardigan, Inc. reported third quarter 2026 financial results, ending the period with $591.4 million in cash to fund operations through 2027. The company achieved significant clinical milestones, including completing enrollment in the Phase 2b portion of its danicamtiv KINSHIP-DCM trial and the Phase 2b KATALYST-AV trial for ataciguat. Topline data for the danicamtiv trial is expected in the second quarter of 2027.
Term
Q3 2026
“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options. Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.”
Tassos Gianakakos, co-founder, chief executive officer and board chair
BCP Investment Corp reported total investment income of $34.8 million for the nine months ended September 30, 2026, compared to $31.1 million in the prior year period. The company's Net Asset Value (NAV) per share decreased to $13.13 from $16.68 at year-end 2025, while total assets declined to $449.5 million as the company manages its portfolio and prepares for a potential merger with Investcorp Credit Management BDC, Inc.
Kiora Pharmaceuticals reported third quarter 2026 financial results and highlighted the strategic in-licensing of KIO-401, a late-stage oral neuroprotective asset for retinal diseases. The company ended the quarter with $16.3 million in cash and is preparing for a Phase 3 registration trial for KIO-401 in patients with Central Retinal Artery Occlusion (CRAO).
“The addition of KIO-401 transforms Kiora into a late-stage retinal therapeutics company. We are building on the significant amount of CMC, non-clinical and clinical data that already exists on KIO-401 through Senju’s previous and ongoing efforts. With exclusive rights outside Asia, we are preparing for a single, phase 3, registration trial of KIO-401 in patients across the United States, Europe and other territories.”
Brian M. Strem, Ph.D., President and Chief Executive Officer
NIQ Global Intelligence reported Q3 2026 financial results, achieving positive GAAP EPS for the first time since its IPO with revenue of $1.12 billion. The company also announced a new $150 million share repurchase program and raised its full-year 2026 guidance following six consecutive quarters of exceeding targets.
“Q3 was a milestone quarter — we exceeded the top end of our guidance across all key metrics for the sixth consecutive quarter, delivered positive GAAP earnings per share for the first time since our IPO, and reached our net leverage milestone a quarter ahead of plan.”
Jim Peck, Executive Chairman and Chief Executive Officer
Rockwell Medical reported net sales of $19.1 million for Q3 2026, a 20% increase over the prior year, though net loss widened to $2.3 million. The company maintained a cash and investment position of $22.5 million while managing a total accumulated deficit of $408.1 million.
RCM Technologies reported net income of $11.5 million for the thirty-nine weeks ended October 3, 2026, an increase from $10.2 million in the prior year period. Revenue grew to $250.3 million compared to $232.9 million, while the company continued its share repurchase program, increasing treasury stock to $91.4 million.
Kiora Pharmaceuticals reported a net loss of $1.75 million for the third quarter of 2026, compared to a small net income of $0.03 million in the prior year period. While the company recognized $1.0 million in collaboration revenue, total operating expenses increased significantly due to a $1.77 million unfavorable swing in the fair value of contingent consideration.
Chicago Atlantic BDC, Inc. reported total investment income of $46.1 million for the nine months ended September 30, 2026, compared to $40.1 million for the same period in 2025. The company is currently in the process of a merger with Chicago Atlantic Real Estate Finance, Inc. (REFI), which is expected to result in REFI merging into the Company.
Chicago Atlantic BDC reported Q3 2026 financial results with total investment income of $15.4 million and net investment income of $8.3 million ($0.36 per share). The company achieved record year-to-date gross originations of $167.4 million, growing its portfolio to its largest size in history with a focus on cannabis operators and lower middle market lending.
“The third quarter continued to show that Chicago Atlantic BDC is uniquely positioned to generate attractive risk adjusted returns with a disciplined focus on capital preservation. This has been a record year for gross originations thus far: we have deployed $167.4 million year to date, including, $72.0 million to two new borrowers in the third quarter, growing the portfolio to the largest size in company history.”
Peter Sack, Chief Executive Officer of the Company
“Our differentiated investment approach has produced a strong and resilient portfolio characterized by stable risk ratings, no investments on non-accrual, and a 100% senior secured debt portfolio, generating a weighted average yield of 15.5%.”
Peter Sack, Chief Executive Officer of the Company
Babcock & Wilcox Enterprises Insider BRC Group Holdings Inc. Buys $648K of Stock
BRC Group Holdings Inc. bought 130,000 shares of Babcock & Wilcox Enterprises, Inc. at $4.98 to $4.98 a share (average $4.98) in 3 transactions, worth $648K in total on Nov 11, 2026. Shares held after the trade: 80,431 (+77.0%).
KBR is hosting an investor day for Trinzic, its planned spin-off of the Mission Technology Solutions business, ahead of its expected launch in January 2027. The presentation outlines Trinzic's strategic framework as an independent national security and space technology company with over $5 billion in annual revenue and a $17.3 billion backlog.
Bit Digital, Inc. reported various investment activities for the quarter ended September 30, 2026, including a $1.0 million SAFE investment in Canopy Wave Inc. and a $33.7 million total investment in AI Innovation Fund I. The company also recorded significant fair value adjustments, notably a $17.1 million upward adjustment for its Innovation Fund I during the three-month period.
Aveanna Healthcare reported revenue of $695.5 million for the third quarter of 2026, up from $621.9 million in the prior year period. The company significantly reduced its accumulated deficit from $1.16 billion at the start of the year to $1.03 billion as of October 3, 2026, while total assets grew to $2.21 billion following the acquisition of Family First Holding, LLC.
Southport Acquisition Corp. II announced that holders of units issued in its initial public offering may elect to separately trade the underlying Class A ordinary shares and warrants starting November 16, 2026. The separated securities will trade on the NYSE under the symbols 'PORT' and 'PORT WS', while unseparated units will continue to trade under 'PORT U'.
D-Wave Quantum Inc. announced its recognition as a 'Market Shaper' in the Gartner Emerging Market Quadrant for Quantum Computing - Established Vendors. The company was one of six vendors placed in the upper right quadrant, reflecting its focus on scalable fault-tolerant architectures and enterprise quantum software stacks.